Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - HC Wainwright lowered their Q1 2027 EPS estimates for Legend Biotech in a note issued to investors on Tuesday, August 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of $0.26 for the quarter, down from their prior forecast of $0.38. HC Wainwright currently has a "Buy" rating and a $65.00 target price on the stock. The consensus estimate for Legend Biotech's current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Legend Biotech's Q2 2027 earnings at $0.36 EPS.
Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.02. The firm had revenue of $387.50 million for the quarter, compared to the consensus estimate of $355.96 million. Legend Biotech had a negative net margin of 7.21% and a negative return on equity of 8.71%. The firm's quarterly revenue was up 51.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.03 EPS.
A number of other brokerages also recently commented on LEGN. TD Cowen reduced their price target on Legend Biotech from $29.00 to $24.00 and set a "hold" rating for the company in a report on Wednesday, August 12th. JPMorgan Chase & Co. began coverage on Legend Biotech in a research report on Monday, July 13th. They issued a "neutral" rating and a $35.00 target price on the stock. Raymond James Financial reissued an "outperform" rating and set a $58.00 price target on shares of Legend Biotech in a research report on Monday, July 27th. Weiss Ratings cut shares of Legend Biotech from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday. Finally, Morgan Stanley boosted their target price on shares of Legend Biotech from $48.00 to $49.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Eight research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Legend Biotech has a consensus rating of "Hold" and a consensus price target of $52.29.
Check Out Our Latest Stock Report on LEGN
Legend Biotech Stock Performance
Shares of NASDAQ LEGN opened at $21.26 on Friday. Legend Biotech has a 1 year low of $16.24 and a 1 year high of $37.50. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of -85.04 and a beta of 0.37. The stock's 50-day simple moving average is $24.86 and its 200-day simple moving average is $23.28.
Institutional Investors Weigh In On Legend Biotech
A number of hedge funds and other institutional investors have recently modified their holdings of LEGN. Suvretta Capital Management LLC boosted its stake in shares of Legend Biotech by 73.1% during the 4th quarter. Suvretta Capital Management LLC now owns 6,608,629 shares of the company's stock worth $143,672,000 after acquiring an additional 2,790,620 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Legend Biotech in the 2nd quarter worth $55,307,000. Goldman Sachs Group Inc. lifted its holdings in shares of Legend Biotech by 120.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,174,535 shares of the company's stock valued at $47,274,000 after purchasing an additional 1,188,449 shares during the last quarter. Davern Capital Partners LP purchased a new stake in shares of Legend Biotech during the fourth quarter valued at $22,972,000. Finally, Marshall Wace LLP boosted its position in shares of Legend Biotech by 4,129.8% in the 4th quarter. Marshall Wace LLP now owns 755,953 shares of the company's stock valued at $16,434,000 after purchasing an additional 738,081 shares during the period. 70.89% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, CEO Ying Huang sold 5,566 shares of the business's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the transaction, the chief executive officer owned 241,872 shares of the company's stock, valued at approximately $3,574,868.16. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.02% of the stock is owned by corporate insiders.
About Legend Biotech
(
Get Free Report)
Legend Biotech NASDAQ: LEGN is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.
The company's lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Legend Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.
While Legend Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
